Skip to main content
Clinical Trials/NCT05955040
NCT05955040
Terminated
Phase 2

Treatment of Elevated Blood Pressures in Early Pregnancy

Marshall University1 site in 1 country2 target enrollmentJuly 11, 2023

Overview

Phase
Phase 2
Intervention
Nifedipine
Conditions
Elevated Blood Pressure
Sponsor
Marshall University
Enrollment
2
Locations
1
Primary Endpoint
Treatment of elevated blood pressures
Status
Terminated
Last Updated
last year

Overview

Brief Summary

This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.

Detailed Description

Patients will be randomized to treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic) versus non-treatment. After randomization to treatment, patient's will be treated with either nifedipine or labetalol (both medications that are standard of care for treatment of elevated blood pressure during pregnancy). The purpose of this study is two-fold: 1) Determine if treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic) versus non-treatment improves maternal and fetal outcomes and 2) determine if ICG directed treatment is optimal as ICG will not be used to determine treatment medication (this will be done by secondary analysis after conclusion of the study).

Registry
clinicaltrials.gov
Start Date
July 11, 2023
End Date
May 6, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jesse Cottrell

Assistant Professor of Maternal Fetal Medicine

Marshall University

Eligibility Criteria

Inclusion Criteria

  • Patients presenting for obstetric care at Marshall University (Huntington office and Teays Valley office) between 12 and 16 weeks gestation with a systolic blood pressure of 120 or greater OR a diastolic blood pressure of 80 or greater. Eligibility for this study will be have blood pressures between 120-139 systolic and 80-89 diastolic. Randomization to control, labetalol, or nifedipine will be performed after patient consent.

Exclusion Criteria

  • Patients already be on medication for hypertension.
  • Patients with the diagnosis of chronic hypertension
  • Patients with a BP of 140 or greater systolic OR 90 or greater diastolic (this meets criteria for chronic hypertension in pregnancy).
  • Patients actively using any illicit substance or have history of substance use disorder.
  • Patients who are actively consuming alcohol during pregnancy.
  • Patients with Type I or Type II Diabetes Mellitus.
  • Patients with end stage renal disease.
  • Patients less then 12 weeks gestation or greater than 16 weeks

Arms & Interventions

Treatment Group

Treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic)

Intervention: Nifedipine

Treatment Group

Treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic)

Intervention: Labetalol

Outcomes

Primary Outcomes

Treatment of elevated blood pressures

Time Frame: through study completion, an average of 1 year

NICU days

Secondary Outcomes

  • ICG directed treatment(through study completion, an average of 1 year)

Study Sites (1)

Loading locations...

Similar Trials